Veracyte Inc. (VCYT)
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VCYT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.03B
- P/E (TTM)
- 16.32
- Forward P/E
- 16.15
- EPS (TTM)
- $1.54
- Dividend yield
- None
- 52-week range
- 21.91 – 60.91
- Day range
- 24.53 – 25.60
- Volume / Avg
- 2.79M / 1.89M
- Beta
- —
- Shares outstanding
- 80.70M
52-week range
VCYT stock today
On Nov 20, VCYT ended the session at $25.13, adding $0.09 (0.36%), versus the S&P 500's 3.70% decline. At this level, VCYT sits near the bottom of its 52-week range of $21.91 to $60.91: 58.7% below the high, set on Jun 30, 2026 and 14.7% above the low. VCYT is down 40.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 42.9%.
At 16.3x trailing earnings, Veracyte trades below the peer-group median of 51.9x. Its forward P/E of 16.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Veracyte
Company profileVeracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Marc A. Stapley
- Headquarters
- South San Francisco, CA
- Employees
- 755
- IPO year
- 2013
- Website
- veracyte.com
Financial highlights
Full financialsIn fiscal 2025, Veracyte generated $517.1 million in revenue, up 16.0% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $66.4 million (+174.9% year over year), for a net margin of 12.8% versus a median of -20.6% in the prior 5 years. Gross margin was 70.1% (up from 66.9%) and operating margin 11.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $517.14M | $445.76M | $361.05M | $296.54M | $219.51M |
| Growth | +16.01% | +23.46% | +21.76% | +35.09% | +86.85% |
| Net income | $66.35M | $24.14M | $-74.40M | $-36.56M | $-75.56M |
| EPS (diluted) | $0.82 | $0.31 | $-1.02 | $-0.51 | $-1.11 |
Analyst forecast
ForecastConsensus (12 analysts)
buy
Avg. price target
$44.60+77.48%
- Strong buy 2
- Buy 7
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.38 vs $0.29
- Surprise
- +31.03%
VCYT news
All VCYT news- VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving VeracytePR Newswire
- Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental testsSeeking Alpha
- Veracyte (VCYT) Q3 2026 Earnings Call TranscriptNasdaq
- Veracyte downgraded at Leerink after guidance cutSeeking Alpha
- Veracyte Crashes Almost 40% On Seismic Shift For Its Best-Selling TestInvestor's Business Daily
- Why is Veracyte stock plummeting today?Investing.com
- Veracyte, Inc. Reports Third Quarter 2026 Financial Results and Announces $100 Million Share Repurchase ProgramNasdaqVCYT, WSO.B
- Veracyte (VCYT) Tops Q3 Earnings and Revenue EstimatesNasdaqVCYT, MTD
Veracyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLOVClover Health Investments Corp. Class A | 3.73 | -1.06% | $2.00B | vs VCYT |
| FTREFortrea Holdings Inc. | 18.55 | -7.94% | $1.79B | vs VCYT |
| PSNLPersonalis Inc. | 14.27 | -3.06% | $1.55B | vs VCYT |
| TRUPTrupanion Inc. | 35.56 | -0.86% | $1.54B | vs VCYT |
| CELCCelcuity Inc. | 53.35 | -5.26% | $2.61B | vs VCYT |
| LMRILumexa Imaging Holdings Inc. | 14.26 | +1.42% | $1.37B | vs VCYT |
| ALHCAlignment Healthcare Inc. | 6.37 | -2.00% | $1.33B | vs VCYT |
| FRNMFreenome Inc. | 9.36 | -5.69% | $1.04B | vs VCYT |
Indexes, lists and sector
Veracyte stock FAQ
What is Veracyte's stock price today?
VCYT last traded at $25.13 as of Nov 20, 4:00 PM EST, up 0.36% on the day. Prices are delayed at least 15 minutes.
What is VCYT's P/E ratio?
VCYT trades at a trailing P/E ratio of 16.32 and a forward P/E of 16.15, compared with a median of 51.9 for its closest peers.
Who is Veracyte's CEO?
Mr. Marc A. Stapley is the chief executive officer of Veracyte Inc., which has about 755 employees.
What is the VCYT 52-week high?
The 52-week high for VCYT is $60.91 and the 52-week low is $21.91. The stock is currently 58.7% below its high.